natgillin/translations-raw huggingface dataset:
Naglazyme is used to treat patients who have mucopolysaccharidosis VI (MPS VI or Maroteaux-Lamy syndrome). 
Zdravilo Naglazyme se uporablja za zdravljenje bolnikov z mukopolisaharidozo VI (MPS VI ali Maroteaux-Lamyjevim sindromom).
Naglazyme should not be used in people who may be hypersensitive (allergic) to galsulfase or any of the other ingredients. 
Zdravila Naglazyme ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) galsulfazo ali katero koli drugo sestavino zdravila.
The CHMP decided that Naglazyme's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Naglazyme večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
This is a summary of the European public assessment report (EPAR) for Naglazyme. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Naglazyme.
What information is still awaited for Naglazyme? 
Katere informacije o zdravilu Naglazyme še pričakujemo?
Patients can also have reactions to the infusion (such as fever, chills, rash and hives). 
Opažene so bile tudi reakcije na infuzijo (kot so povišana telesna temperatura, mrazenje, izpuščaji in koprivnica).
The full EPAR for Naglazyme can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Naglazyme je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This disease is caused by the lack of an enzyme called N-acetylgalactosamine 4-sulfatase, which is needed to break down substances in the body called glycosaminoglycans (GAGs). 
To bolezen povzroča pomanjkanje encima, imenovanega Nacetilgalaktozamin-4-sulfataza, ki je potreben za razgradnjo snovi v telesu, imenovanih glikozaminoglikani (GAG).
Patients may also be given a medicine to prevent fever. 
Lahko pa prejme tudi zdravilo za preprečevanje zvišanja telesne temperature.
The Committee noted that, although patients under five years of age were not included in the main study of Naglazyme, it is important that they are treated if they have a severe form of MPS VI. Naglazyme has been authorised under ‘exceptional circumstances'. 
Odbor je opozoril, da je za bolnike, mlajše od pet let, pomembno, da prejemajo zdravljenje, če imajo hudo obliko MPS VI, čeprav niso bili vključeni v glavno študijo z zdravilom Naglazyme.
Why has Naglazyme been approved? 
Zakaj je bilo zdravilo Naglazyme odobreno?
The active substance in Naglazyme, galsulfase, is a copy of the human enzyme N-acetylgalactosamine 4-sulfatase. 
Zdravilna učinkovina zdravila Naglazyme, galsulfaza, je kopija humanega encima N-acetilgalaktozamin-4-sulfataze.
Naglazyme is a solution for infusion (drip into a vein) that contains the active substance galsulfase (1 mg/ml). 
Zdravilo Naglazymeje raztopina za infuzijo (kapalno infuzijo v veno), ki vsebuje zdravilno učinkovino galsulfazo (1 mg/ml).
Naglazyme helps to break down the GAGs and stop them building up in the cells. 
Zdravilo Naglazyme prispeva k razgradnji glikozaminoglikanov in ustavi njihovo kopičenje v celicah.
Naglazyme is an enzyme replacement therapy. 
Zdravilo Naglazyme je zdravilo za encimsko nadomestno zdravljenje.
For the full list of all side effects reported with Naglazyme, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Naglazyme, glejte navodilo za uporabo.
What is Naglazyme used for? 
Za kaj se zdravilo Naglazyme uporablja?
How is Naglazyme used? 
Kako se zdravilo Naglazyme uporablja?
Other information about Naglazyme 
Druge informacije o zdravilu Naglazyme
How has Naglazyme been studied? 
Kako je bilo zdravilo Naglazyme raziskano?
The European Commission granted a marketing authorisation valid throughout the European Union for Dafiro HCT on 4 November 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Dafiro HCT, veljavno po vsej Evropski uniji, odobrila dne 4. novembra 2009.
The full EPAR for Dafiro HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Dafiro HCT je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It is available as tablets containing amlodipine, valsartan and hydrochlorothiazide in the following amounts: 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg; 10/160/25 mg and 10/320/25 mg. 
Na voljo je v obliki tablet, ki vsebujejo amlodipin, valsartan in hidroklorotiazid v naslednjih količinah: 5/160/12,5 mg, 10/160/12,5 mg, 5/160/25 mg, 10/160/25 mg in 10/320/25 mg.
This is a summary of the European public assessment report (EPAR) for Dafiro HCT. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Dafiro HCT.
For more information about treatment with Dafiro HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Dafiro HCT preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The main study showed the benefit of the highest strength of Dafiro HCT in lowering the blood pressure. 
Glavna študija je pokazala koristnost uporabe največjega odmerka zdravila Dafiro HCT pri zniževanju krvnega tlaka.
The CHMP therefore decided that Dafiro HCT's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Dafiro HCT večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Dafiro HCT is taken by mouth as one tablet once a day, at the same time of the day and preferably in the morning. 
Zdravilo Dafiro HCT se jemlje peroralno, in sicer se zaužije ena tableta enkrat na dan ob isti uri, če je le mogoče, zjutraj.
The three active substances in Dafiro HCT are anti-hypertensive medicines that are already in use in the European Union (EU). 
Tri zdravilne učinkovine v zdravilu Dafiro HCT so zdravila proti zvišanemu krvnemu tlaku, ki se že uporabljajo v Evropski uniji (EU).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Dafiro HCT. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Dafiro HCT, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
For all doses, Dafiro HCT also met requirements to prove that it was comparable to the combinations of the individual active substances taken separately. 
Pri vseh odmerkih je zdravilo Dafiro HCT izpolnilo tudi zahteve, s katerimi je bilo dokazano, da je primerljivo s kombinacijami posameznih zdravilnih učinkovin, vzetih ločeno.
Dafiro HCT is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of amlodipine, valsartan and hydrochlorothiazide. 
Zdravilo Dafiro HCT se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih, pri katerih je krvni tlak že ustrezno uravnan z uporabo kombinacije amlodipina, valsartana in hidroklorotiazida.
The average reduction in blood pressure was around 39.7/24.7 mmHg in patients taking Dafiro HCT compared with 32/19.7 mmHg, 33.5/21.5 mmHg and 31.5/19.5 mmHg in patients taking valsartan/hydrochlorothiazide, valsartan/amlodipine and hydrochlorothiazide/amlodipine combinations, respectively. 
Povprečno znižanje krvnega tlaka je bilo okrog 39,7/24,7 mmHg pri bolnikih, ki so prejemali zdravilo Dafiro HCT, v primerjavi z 32/19,7 mmHg pri bolnikih, ki so prejemali kombinacije valsartan/hidroklorotiazid, 33,5/21,5 mmHg pri bolnikih, ki so prejemali kombinacije valsartan/amlodipin, in 31,5/19,5 mmHg pri bolnikih, ki so prejemali kombinacije hidroklorotiazid/amlodipin.
The most common side effects with Dafiro HCT (seen in between 1 and 10 patients in 100) are hypokalaemia (low blood potassium levels), dizziness, headache, hypotension (low blood pressure), dyspepsia (heartburn), pollakiuria (abnormally frequent urination), fatigue (tiredness) and oedema (fluid retention). 
Najpogostejši neželeni učinki zdravila Dafiro HCT (opaženi pri 1 do 10 bolnikih od 100) so hipokaliemija (nizka raven kalija v krvi), omotica, glavobol, hipotenzija (nizek krvni tlak), dispepsija (zgaga), polakisurija (neobičajno pogosto uriniranje), utrujenost in edem (zadrževanje tekočine).
Dafiro HCT is a medicine that contains three active substances, amlodipine, valsartan and hydrochlorothiazide. 
Dafiro HCT je zdravilo, ki vsebuje tri zdravilne učinkovine amlodipin, valsartan in hidroklorotiazid.
The daily dose of Dafiro HCT should not exceed 10 mg of amlodipine, 320 mg of valsartan and 25 mg of hydrochlorothiazide. 
Dnevni odmerek učinkovin zdravila Dafiro HCT ne sme biti večji od 10 mg amlodipina, 320 mg valsartana in 25 mg hidroklorotiazida.
For the full list of all side effects reported with Dafiro HCT, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Dafiro HCT, glejte navodilo za uporabo.
The dose of Dafiro HCT to be used is the same as the doses of three individual active substances that the patient was taking before. 
Odmerek učinkovin zdravila Dafiro HCT mora biti enak odmerkom treh posameznih zdravilnih učinkovin, ki jih je bolnik jemal pred tem.
What benefit has Dafiro HCT shown during the studies? 
Kakšne koristi je zdravilo Dafiro HCT izkazalo med študijami?
Treatment with the highest strength of Dafiro HCT was more effective at treating hypertension than dual combinations containing any of the two active substances. 
Zdravljenje z največjim odmerkom zdravila Dafiro HCT je bilo pri zdravljenju hipertenzije učinkovitejše od zdravljenja z dvojnimi kombinacijami, ki so vsebovale po dve zdravilni učinkovini.
Dafiro HCT must not be used in people who are hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Dafiro HCT. 
Zdravila Dafiro HCT ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) zdravilne učinkovine zdravila, druge sulfonamide, derivate dihidropiridina ali katero koli drugo sestavino zdravila
What is the risk associated with Dafiro HCT? 
Kakšna tveganja so povezana z zdravilom Dafiro HCT?
Finally, Dafiro HCT must not be used in patients with hypokalaemia (low blood potassium levels), hyponatraemia (low blood sodium levels) and hypercalcaemia (high blood calcium levels) that do not respond to treatment and in patients with hyperuricaemia (high blood levels of uric acid) that causes symptoms. 
Zdravila Dafiro HCT poleg tega ne smejo uporabljati bolniki s hipokaliemijo (nizko ravnjo kalija v krvi), hiponatriemijo (nizko ravnjo natrija v krvi) in hiperkalciemijo (visoko ravnjo kalcija v krvi), ki se ne odzivajo na zdravljenje, ter bolniki s simptomatsko hiperurikemijo (visoko koncentracijo sečne kisline v krvi).
Other information about Dafiro HCT 
Druge informacije o zdravilu Dafiro HCT
Dafiro HCT must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment. 
Prav tako se ne sme uporabljati v kombinaciji z zdravili, ki vsebujejo aliskiren (ki se uporablja za zdravljenje esencialne hipertenzije), pri bolnikih s sladkorno boleznijo tipa 2 ali zmerno do hudo ledvično okvaro.
Why has Dafiro HCT been approved? 
Zakaj je bilo zdravilo Dafiro HCT odobreno?
In addition, one main study was carried out in 2,271 patients with moderate to severe hypertension with the highest strength of Dafiro HCT (320 mg valsartan, 10 mg amlodipine and 25 mg hydrochlorothiazide). 
Poleg tega je bila izvedena glavna študija, v kateri so proučevali 2 271 bolnikov z zmerno do hudo hipertenzijo, ki so prejemali največji odmerek zdravila Dafiro HCT (320 mg valsartana, 10 mg amlodipina in 25 mg hidroklorotiazida) Bolniki so osem tednov prejemali bodisi zdravilo Dafiro HCT bodisi eno od treh kombinacij, ki so vsebovale le dve zdravilni učinkovini.
The CHMP noted that patients already taking the three active substances would be more likely to comply with their treatment if prescribed Dafiro HCT which combines the three substances in a single tablet. 
CHMP je menil, da bi uporaba zdravila Dafiro HCT, pri katerem so tri zdravilne učinkovine prisotne v eni tableti, bolnikom, ki tri zdravilne učinkovine že prejemajo ločeno, omogočila doslednejše jemanje zdravila.
How has Dafiro HCT been studied? 
Kako je bilo zdravilo Dafiro HCT raziskano?
What is Dafiro HCT? 
Kaj je zdravilo Dafiro HCT?
How is Dafiro HCT used? 
Kako se zdravilo Dafiro HCT uporablja?
How does Dafiro HCT work? 
Kako zdravilo Dafiro HCT deluje?
• The role and use of the Patient Alert Card 
Vloga in uporaba Opozorilne kartice za bolnika.
• Who have a history of Torsades de Pointes unless all risk factors that contributed to Torsades have been corrected. 
ki imajo Torsades de pointes v anamnezi, razen če so bili vsi dejavniki tveganja, ki so prispevali k Torsades, odpravljeni.
• The need to counsel patients about the risk of prolonged QTc and PRES and inform them of what symptoms and signs to be aware of and the actions to take 
Potreba po svetovanju bolnikom glede tveganj za podaljšanje intervala QTc in PRES ter seznanitev bolnikov o simptomih in znakih na katere morajo biti pozorni ter kako je treba ukrepati.
• That vandetanib may cause Posterior reversible encephalopathy syndrome (PRES) also known as Reversible posterior leukoencephalopathy syndrome (RPLS) 
Da lahko vandetanib povzroči sindrom posteriorne reverzibilne encefalopatije (PRES), znan tudi kot sindrom reverzibilne posteriorne levkoencefalopatije (RPLS).
• PRES should be considered in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function. 
PRES je treba upoštevati pri katerem koli bolniku, ki se mu pojavijo krči, glavobol, motnje vida, zmedenost ali motnje zavesti.
• If QTc increases markedly but stays below 500 msec, the advice of a cardiologist should be sought. 
Če se interval QTc znatno podaljša, vendar ostane krajši od 500 ms, je treba poiskati nasvet kardiologa.
The Marketing Authorisation Holder (MAH) should ensure that, at launch and thereafter, all Healthcare Professionals who are expected to use and/or prescribe Caprelsa are provided with an Educational pack. 
Imetnik dovoljenja za promet mora zagotoviti, da bo po prihodu zdravila na tržišče in zatem, zdravstvenemu osebju, za katere bo pričakovati, da bo uporabljalo in/ali predpisovalo zdravilo Caprelsa, priskrbel paket izobraževalnega gradiva.
Dosing can be resumed at a reduced dose after return of the ECG QTc interval to pretreatment status has been confirmed and correction of possible electrolyte imbalance has been made. 
Odmerjanje je mogoče znova uvesti v manjšem odmerku, ko je potrjeno, da je interval QTc spet takšen kot pred zdravljenjem in, da je morebitno elektrolitsko neravnovesje popravljeno.
• Patients who develop a single value of corrected ECG QTc interval of at least 500 msec should stop taking vandetanib. 
Bolniki, ki se jim na EKG pojavi ena sama vrednost korigiranega intervala QTc v vrednosti vsaj 500 ms, morajo prenehati z jemanjem vandetaniba.
• The need for an ECG, and serum levels of potassium, calcium and magnesium and thyroid stimulating hormone (TSH) and the times and situations when it should be performed 
Trenutki in okoliščine kadar je treba izvesti preiskavo EKG, določitev serumskih ravni kalija, kalcija in magnezija ter tiroideo-stimulirajočega hormona.
• Details of medicinal products where the co-administration of vandetanib is either contraindicated or not recommended. 
Podrobnosti glede zdravil s katerimi je sočasno dajanje ali kontraindicirano ali pa ni priporočljivo.
• Vandetanib prolongs the QTc interval and can cause Torsades de Pointes and sudden death 
Izobraževalno gradivo za zdravstveno osebje mora vsebovati naslednje ključne elemente: Vandetanib podaljša interval QTc in lahko sproži Torsades de pointes in nenadno smrt.
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented: 
Pogoji in omejitve glede varne in učinkovite uporabe zdravila, ki jih bodo uveljavile države članice Države članice morajo zagotoviti, da bodo vsi pogoji ali omejitve glede varne in učinkovite uporabe zdravila, kot je opisano spodaj, uveljavljene: Pred prihodom zdravila na tržišče v vsaki državi članici se bo imetnik dovoljenja za promet dogovoril glede vsebine in oblike izobraževalnega gradiva z nacionalnim organom, pristojnim za zdravila.
• Whose ECG QTc interval is greater than 480 msec 
Zdravljenja z vandetanibom se ne sme uvesti pri bolnikih: pri katerih je interval QTc daljši od 480 ms, ki imajo sindrom prirojenega podaljšanja intervala QTc.
The educational material for Healthcare Professionals should contain the following key elements: 
Paket izobraževalnega gradiva bi naj vseboval naslednje: Povzetek glavnih značilnosti zdravila in Navodilo za uporabo, Izobraževalno gradivo za zdravstveno osebje, Opozorilno kartico za bolnika (besedilo usklajeno s CHMP).
Restrictions on the use of methysergide-containing medicines 
Omejitev uporabe zdravil, ki vsebujejo metizergid
The pharmaceutical forms and the approved indications, strengths and doses vary in different EU countries. 
Farmacevtske oblike ter odobrene indikacije, jakosti in odmerki se v posameznih državah EU razlikujejo.
This examination should include a re-assessment of the benefit-risk balance in the individual patient. 
Pregled mora vključevati ponovno oceno razmerja med tveganji in koristmi pri posameznem bolniku.
In the EU, medicines containing methysergide have been authorised by national procedures and have been marketed under various trade names. 
Zdravila, ki vsebujejo metizergid, so bila v EU odobrena po nacionalnih postopkih in se tržijo pod različnimi tržnimi imeni.
The review of methysergide was initiated on 24 May 2012 at the request of the French medicines agency ANSM under Article 31 of Directive 2001/83/EC following concerns about serious cases of fibrosis identified by the French agency. 
Pregled metizergida je bil sprožen 24. maja 2012 na zahtevo francoske agencije za zdravila (ANSM) v skladu s členom 31 Direktive 2001/83/ES, potem ko so se pojavili pomisleki zaradi resnih primerov fibroze, ki jih je odkrila francoska agencija.
The CHMP opinion was sent to the European Commission, which endorsed it and issued a final legally binding decision on 28 April 2014. 
Odbor CHMP je mnenje predložil Evropski komisiji, ki ga je potrdila in 28. aprila 2014 izdala končni pravno zavezujoči sklep.
The Agency's recommendations are based on available data on the benefits and risks of methysergide, from clinical studies, post-marketing safety reports and the scientific literature. 
Priporočila agencije temeljijo na razpoložljivih podatkih o koristih in tveganjih, povezanih z metizergidom, iz kliničnih študij, poročil o varnosti zdravila iz obdobja trženja in znanstvene literature.
• Following the review of methysergide-containing medicines, methysergide should now only be used for: 
• V skladu z izidom pregleda zdravil, ki vsebujejo metizergid, se lahko metizergid odslej uporablja samo za:
If you are being treated for this purpose, please contact your doctor to discuss alternative treatment. 
Če zdravilo uporabljate za ta namen, se posvetujte z zdravnikom o drugih možnostih zdravljenja.
The symptoms of fibrosis often take some time to appear and without screening the diagnosis may come too late to prevent severe (and potentially life-threatening) damage to organs . 
Simptomi fibroze se pogosto pojavijo šele čez nekaj časa, zato se lahko brez presejalnih preiskav diagnoza postavi prepozno, da bi lahko preprečili hude (in morda smrtno nevarne) poškodbe organov.
The CHMP recommendations were sent to the European Commission, which has endorsed them and issued a final legally-binding decision that is valid throughout the EU. 
Odbor CHMP je priporočila predložil Evropski komisiji, ki jih je potrdila in izdala končni pravno zavezujoči sklep, ki velja za celotno EU.
However, there were no data to support this use and Methysergide should therefore no longer be used in carcinoid disease. 
Vendar tovrstne uporabe ne podpirajo nobeni podatki, zato se metizergid pri karcinoidni bolezni ne sme več uporabljati.
Based on these data a potential causal association between methysergide and fibrosis seems likely. 
Glede na te podatke se morebitna vzročna povezava med metizergidom in fibrozo zdi verjetna.
The Agency's Committee for Medicinal Products for Human Use (CHMP), which conducted the review, noted that these recommendations were necessary due to the reports of fibrosis seen with methysergide and other medicines of the same class (ergot derivatives). 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji, ki je opravil pregled, je izpostavil, da so bila ta priporočila nujno potrebna zaradi poročil o fibrozi, ki so jo opažali pri uporabi metizergida in drugih zdravil iz iste skupine (derivati ergot alkaloidov).
The prescribing information for physicians and information in the patients' information leaflet has been updated. 
Navodila za zdravnike glede predpisovanja zdravil in informacije v navodilu za uporabo so bile posodobljene.
• Your doctor will also regularly re-assess the need for you to continue treatment with methysergide by seeing if your symptoms return after periodic breaks in treatment. 
• Zdravnik bo prav tako redno ocenjeval, ali pri vas še obstaja potreba po nadaljnjem zdravljenju z metizergidom, tako da bo preveril, ali se vaši simptomi po občasnih prekinitvah zdravljenja ponovno pojavijo.
• If you are using methysergide to prevent migraines and cluster headaches, your doctor will check on a regular basis whether you are developing any signs or symptoms of fibrosis. 
• Če metizergid uporabljate za preprečevanje migren in glavobolov v rafalih, bo zdravnik redno preverjal, ali so se pri vas morda pojavili kateri koli znaki ali simptomi fibroze.
The mechanism by which methysergide could cause fibrosis through serotoninergic-receptor activation is widely described in the literature. 
Mehanizem, prek katerega bi metizergid z aktivacijo serotoninergičnih receptorjev lahko povzročil fibrozo, je obsežno opisan v literaturi.
Methysergide is a medicine that belongs to the class ‘ergot alkaloids' that has been used in the EU for preventing migraines (with or without aura) and other types of throbbing headaches. 
Metizergid je zdravilo, ki spada v skupino „ergot alkaloidov“, ki se v EU uporabljajo za preprečevanje migren (z avro ali brez nje) ter drugih vrst utripajočih glavobolov.
On 20 February 2014, the European Medicines Agency recommended restricting the use of methysergide due to concerns that it could cause fibrosis, a condition in which fibrous (scar) tissue accumulates in the body's organs potentially damaging them. 
Evropska agencija za zdravila je 20. februarja 2014 priporočila omejitev uporabe metizergida zaradi skrbi, da bi lahko povzročal fibrozo, tj. bolezen, pri kateri se v telesnih organih nabira fibrozno (brazgotinsko) tkivo, ki jih lahko poškoduje.
Regarding the benefits, the Committee noted that there is some evidence of a clinically relevant effect of methysergide when used for prevention in patients who regularly get migraines and cluster headaches and for whom treatment options are limited. 
Kar zadeva koristi, je odbor menil, da obstaja nekaj dokazov o klinično pomembnem učinku metizergida, kadar se uporablja za preprečevanje migren in glavobolov v rafalih pri bolnikih, pri katerih se ti redno pojavljajo in ki imajo omejene možnosti zdravljenja.